Fda approval lenalidomide patent expiry?

When Does Lenalidomide Patent Expire?

Lenalidomide, also known as Revlimid, is a medication used to treat multiple myeloma and myelodysplastic syndromes. It was first approved by the FDA in 2005.

Exclusivity Timeline:

Revlimid was originally approved under the orphan drug designation, granted by the FDA in 2001 for the treatment of multiple myeloma.[1] Lenalidomide was initially developed by Celgene Corporation, now part of Bristol Myers Squibb (BMS).

As of 2005, the orphan drug exclusivity for lenalidomide expired in 2015 according to DrugPatentWatch.com [2]. However, patents and related exclusivity arrangements may still be in place affecting its availability in some markets.

Patent Expirations:

Patents for lenalidomide in different jurisdictions have been expiring over the years. For instance, the last US patent for lenalidomide expired in 2018.[3]

Impact on Access to Lenalidomide:

The expiration of patents and exclusivity arrangements may lead to increased competition and potential price reductions for lenalidomide, making it more accessible to patients. However, this doesn't necessarily guarantee universal affordability due to ongoing market competition, healthcare reimbursement, and regulatory considerations.

What's Next for Lenalidomide?

As lenalidomide becomes more widely available, biosimilar options are being developed and assessed for approval. Companies are racing to bring cost-effective alternatives to market, which may improve patient access.

References:

[1] US FDA | [4th Quarter 2005] Revlimid (lenalidomide) capsules, for injection

[2] DrugPatentWatch.com | Lenalidomide patent (US)

[3] DrugPatentWatch.com | Lenalidomide patent (US) expiration date

Note: The availability, efficacy, and regulatory status of lenalidomide and biosimilar alternatives may vary in different jurisdictions.